Cargando…
Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
BACKGROUND: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30 years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of Leishmania to these drugs is unknown despite clinical evide...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031164/ https://www.ncbi.nlm.nih.gov/pubmed/24853871 http://dx.doi.org/10.1371/journal.pntd.0002871 |
_version_ | 1782317493313863680 |
---|---|
author | Fernández, Olga Lucía Diaz-Toro, Yira Ovalle, Clemencia Valderrama, Liliana Muvdi, Sandra Rodríguez, Isabel Gomez, María Adelaida Saravia, Nancy Gore |
author_facet | Fernández, Olga Lucía Diaz-Toro, Yira Ovalle, Clemencia Valderrama, Liliana Muvdi, Sandra Rodríguez, Isabel Gomez, María Adelaida Saravia, Nancy Gore |
author_sort | Fernández, Olga Lucía |
collection | PubMed |
description | BACKGROUND: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30 years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of Leishmania to these drugs is unknown despite clinical evidence supporting the emergence of resistance. METHODOLOGY/PRINCIPAL FINDINGS: In vitro susceptibility was determined for intracellular amastigotes of 245 clinical strains of the most prevalent Leishmania Viannia species in Colombia to miltefosine (HePC) and/or meglumine antimoniate (Sb(V)); 163, (80%) were evaluated for both drugs. Additionally, susceptibility to Sb(V) was examined in two cohorts of 85 L. V. panamensis strains isolated between 1980–1989 and 2000–2009 in the municipality of Tumaco. Susceptibility to each drug differed among strains of the same species and between species. Whereas 68% of L. V. braziliensis strains presented in vitro resistance to HePC, 69% were sensitive to Sb(V). Resistance to HePC and Sb(V) occurred respectively, in 20% y 21% of L. panamensis strains. Only 3% of L. V. guyanensis were resistant to HePC, and none to Sb(V). Drug susceptibility differed between geographic regions and time periods. Subpopulations having disparate susceptibility to Sb(V) were discerned among L. V. panamensis strains isolated during 1980–1990 in Tumaco where resistant strains belonged to zymodeme 2.3, and sensitive strains to zymodeme 2.2. CONCLUSIONS/SIGNIFICANCE: Large scale evaluation of clinical strains of Leishmania Viannia species demonstrated species, population, geographic, and epidemiologic differences in susceptibility to meglumine antimoniate and miltefosine, and provided baseline information for monitoring susceptibility to these drugs. Sensitive and resistant clinical strains within each species, and zymodeme as a proxy marker of antimony susceptibility for L. V. panamensis, will be useful in deciphering factors involved in susceptibility and the distribution of sensitive and resistant populations. |
format | Online Article Text |
id | pubmed-4031164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40311642014-05-28 Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia Fernández, Olga Lucía Diaz-Toro, Yira Ovalle, Clemencia Valderrama, Liliana Muvdi, Sandra Rodríguez, Isabel Gomez, María Adelaida Saravia, Nancy Gore PLoS Negl Trop Dis Research Article BACKGROUND: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30 years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of Leishmania to these drugs is unknown despite clinical evidence supporting the emergence of resistance. METHODOLOGY/PRINCIPAL FINDINGS: In vitro susceptibility was determined for intracellular amastigotes of 245 clinical strains of the most prevalent Leishmania Viannia species in Colombia to miltefosine (HePC) and/or meglumine antimoniate (Sb(V)); 163, (80%) were evaluated for both drugs. Additionally, susceptibility to Sb(V) was examined in two cohorts of 85 L. V. panamensis strains isolated between 1980–1989 and 2000–2009 in the municipality of Tumaco. Susceptibility to each drug differed among strains of the same species and between species. Whereas 68% of L. V. braziliensis strains presented in vitro resistance to HePC, 69% were sensitive to Sb(V). Resistance to HePC and Sb(V) occurred respectively, in 20% y 21% of L. panamensis strains. Only 3% of L. V. guyanensis were resistant to HePC, and none to Sb(V). Drug susceptibility differed between geographic regions and time periods. Subpopulations having disparate susceptibility to Sb(V) were discerned among L. V. panamensis strains isolated during 1980–1990 in Tumaco where resistant strains belonged to zymodeme 2.3, and sensitive strains to zymodeme 2.2. CONCLUSIONS/SIGNIFICANCE: Large scale evaluation of clinical strains of Leishmania Viannia species demonstrated species, population, geographic, and epidemiologic differences in susceptibility to meglumine antimoniate and miltefosine, and provided baseline information for monitoring susceptibility to these drugs. Sensitive and resistant clinical strains within each species, and zymodeme as a proxy marker of antimony susceptibility for L. V. panamensis, will be useful in deciphering factors involved in susceptibility and the distribution of sensitive and resistant populations. Public Library of Science 2014-05-22 /pmc/articles/PMC4031164/ /pubmed/24853871 http://dx.doi.org/10.1371/journal.pntd.0002871 Text en © 2014 Fernández et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Fernández, Olga Lucía Diaz-Toro, Yira Ovalle, Clemencia Valderrama, Liliana Muvdi, Sandra Rodríguez, Isabel Gomez, María Adelaida Saravia, Nancy Gore Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia |
title | Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia |
title_full | Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia |
title_fullStr | Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia |
title_full_unstemmed | Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia |
title_short | Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia |
title_sort | miltefosine and antimonial drug susceptibility of leishmania viannia species and populations in regions of high transmission in colombia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031164/ https://www.ncbi.nlm.nih.gov/pubmed/24853871 http://dx.doi.org/10.1371/journal.pntd.0002871 |
work_keys_str_mv | AT fernandezolgalucia miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT diaztoroyira miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT ovalleclemencia miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT valderramaliliana miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT muvdisandra miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT rodriguezisabel miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT gomezmariaadelaida miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia AT saravianancygore miltefosineandantimonialdrugsusceptibilityofleishmaniavianniaspeciesandpopulationsinregionsofhightransmissionincolombia |